Bio-Rad Laboratories' stock plummeted 6.89% during intraday trading on Friday, following a target price reduction by analyst firm Jefferies.
Jefferies cut its price target for Bio-Rad Laboratories to $275 from $280, indicating a more cautious outlook on the company's valuation prospects.
Analyst target price revisions often serve as catalysts for stock price movements as investors adjust their positions based on changing professional assessments.